{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:16:55Z","timestamp":1789834615466,"version":"4.0.1"},"reference-count":173,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.autrev.2025.103760","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:06:17Z","timestamp":1738411577000},"page":"103760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus"],"prefix":"10.1016","volume":"24","author":[{"given":"Elena","family":"Bartoloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cacciapaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Erre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garifallia","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103760_bb0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00392-023-02291-4","article-title":"Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis","volume":"113","author":"Asenjo-Lobos","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0010","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2006.052506","article-title":"Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis","volume":"66","author":"Turesson","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0020","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s10067-023-06608-6","article-title":"Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review","volume":"42","author":"Katayama","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0025","first-page":"1789","article-title":"Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus","volume":"35","author":"Rho","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0030","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","article-title":"Role of inflammation in atherosclerosis associated with rheumatoid arthritis","volume":"121","author":"Libby","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00281-022-00922-y","article-title":"Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus","volume":"44","author":"Oliveira","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2025.103760_bb0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/acr2.1035","article-title":"Association of lupus nephritis with coronary artery disease by ISN\/RPS classification: results from a large real-world lupus population","volume":"1","author":"Sun","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0045","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3116","article-title":"Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness","volume":"12","author":"S\u00f6dergren","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autrev.2015.10.002","article-title":"Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis","volume":"15","author":"Wu","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103760_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.autrev.2010.07.016","article-title":"From endothelial dysfunction to atherosclerosis","volume":"9","author":"Sitia","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103760_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1741-7015-12-47","article-title":"Is atherosclerosis an autoimmune disease?","volume":"12","author":"Matsuura","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102863","article-title":"Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus","volume":"132","author":"Liu","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103760_bb0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0075","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/jcm12041302","article-title":"Do Interleukin-1 and Interleukin-6 antagonists hold any place in the treatment of atherosclerotic cardiovascular disease and related co-morbidities? An overview of available clinical evidence","volume":"12","author":"Dimosiari","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0080","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00296-023-05492-2","article-title":"Exercise therapy for improving cardiovascular health in rheumatoid arthritis","volume":"44","author":"Coskun","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103760_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152128","article-title":"Benefits & risks of physical activity in patients with systemic lupus erythematosus: a systematic review of the literature","volume":"58","author":"Blaess","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/CRD.0000000000000124","article-title":"High-intensity interval training versus moderate-intensity continuous training in the prevention\/management of cardiovascular disease","volume":"24","author":"Hussain","year":"2016","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.autrev.2025.103760_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-018-1624-x","article-title":"Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study","volume":"20","author":"Bartlett","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/art.1780400206","article-title":"Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity","volume":"40","author":"Tak","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41584-022-00790-8","article-title":"Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission","volume":"18","author":"Kurowska-Stolarska","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","article-title":"Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus","volume":"73","author":"Ronda","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0120","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/jcm9072157","article-title":"Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after Tocilizumab treatment: a pilot Ssudy","volume":"9","author":"Greco","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0125","article-title":"Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis","volume":"7","author":"Karpouzas","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2025.103760_bb0130","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/annrheumdis-2017-212647","article-title":"Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation","volume":"77","author":"Zeisbrich","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0135","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0140","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"Ronda","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/312647","article-title":"Infliximab reverses suppression of cholesterol efflux proteins by TNF-\u03b1: a possible mechanism for modulation of atherogenesis","volume":"2014","author":"Voloshyna","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2025.103760_bb0150","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/rheumatology\/keab467","article-title":"Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis","volume":"61","author":"Takala","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103760_bb0155","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41467-024-44868-1","article-title":"Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease","volume":"15","author":"Walker","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103760_bb0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH11-09-0650","article-title":"Presence of luminal neutrophil extracellular traps in atherosclerosis","volume":"107","author":"Megens","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103760_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2017.04.007","article-title":"Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in rheumatoid arthritis patients","volume":"82","author":"P\u00e9rez-S\u00e1nchez","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103760_bb0170","first-page":"87","article-title":"Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl res","volume":"183","author":"Ruiz-Lim\u00f3n","year":"2017","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103760_bb0180","doi-asserted-by":"crossref","first-page":"13571361","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103760_bb0185","article-title":"Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis","volume":"9","author":"Li","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103760_bb0190","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3899\/jrheum.141529","article-title":"Genetic variants of the NLRP3 Inflammasome are associated with stroke in patients with rheumatoid arthritis","volume":"42","author":"Kastbom","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0195","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1038\/s41598-017-07574-1","article-title":"Endothelial dysfunction in systemic lupus erythematosus \u2013 a case-control study and an updated meta-analysis and meta-regression","volume":"7","author":"Mak","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103760_bb0200","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2003-09-3198","article-title":"Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity","volume":"103","author":"Rajagopalan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103760_bb0205","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/art.27442","article-title":"Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity","volume":"62","author":"Wang","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2010.01.005","article-title":"Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity","volume":"129","author":"Shah","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2025.103760_bb0215","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/art.21130","article-title":"Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus","volume":"52","author":"Morgan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0220","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.1600108","article-title":"IFN-\u03b1 negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus","volume":"199","author":"Buie","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0225","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103760_bb0230","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000508","article-title":"Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus","volume":"3","author":"Tyd\u00e9n","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103760_bb0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2025.103760_bb0245","doi-asserted-by":"crossref","first-page":"3424136","DOI":"10.1155\/2018\/3424136","article-title":"Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus","volume":"2018","author":"Floris","year":"2018","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2025.103760_bb0250","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0255","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4049\/jimmunol.1202388","article-title":"Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages","volume":"190","author":"Kahlenberg","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0260","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2012.14","article-title":"Accelerated atherosclerosis in patients with SLE\u2014mechanisms and management","volume":"8","author":"Skaggs","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0265","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose Immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clim.2004.02.015","article-title":"Endothelial cell activation by antiphospholipid antibodies","volume":"112","author":"Meroni","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174572","article-title":"Excess atherosclerosis in systemic lupus erythematosus,\u2014a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls","volume":"12","author":"Gustafsson","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103760_bb0280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/acr.20365","article-title":"Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis","volume":"63","author":"Rho","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0285","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1074\/jbc.M209634200","article-title":"Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4\/MD-2, and inhibits phagocytosis of apoptotic cells","volume":"278","author":"Miller","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2025.103760_bb0290","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0022-2275(20)31631-X","article-title":"A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages","volume":"42","author":"Kobayashi","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0295","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0300","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103760_bb0305","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/03009740802007514","article-title":"Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus","volume":"37","author":"Svenungsson","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0310","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/ar3264","article-title":"The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus","volume":"13","author":"Kahlenberg","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0315","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.4238\/2015.November.18.52","article-title":"Vulnerability of atherosclerotic plaques is associated with type I interferon in a murine model of lupus and atherosclerosis","volume":"14","author":"Zhang","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99276","article-title":"Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus","volume":"3","author":"Carlucci","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103760_bb0325","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00011-021-01504-8","article-title":"The role of NK cells in rheumatoid arthritis","volume":"70","author":"Fathollahi","year":"2021","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.imlet.2010.11.001","article-title":"The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?","volume":"136","author":"Ahern","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2025.103760_bb0335","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrcardio.2017.2","article-title":"Natural killer T cells in atherosclerosis","volume":"14","author":"Getz","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0340","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/rheumatology\/keq457","article-title":"Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity","volume":"50","author":"Cho","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103760_bb0345","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.20030997","article-title":"CD1d-dependent activation of NKT cells aggravates atherosclerosis","volume":"199","author":"Tupin","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1160\/TH09-01-0020","article-title":"Effect of natural killer T cell activation on the initiation of atherosclerosis","volume":"102","author":"van Puijvelde","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103760_bb0355","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fimmu.2017.01422","article-title":"Interactions between innate lymphoid cells and cells of the innate and adaptive immune system","volume":"8","author":"Symowski","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0360","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fimmu.2019.00634","article-title":"Non-cytotoxic cardiac innate lymphoid cells are a resident and quiescent type 2-commited population","volume":"10","author":"Bracamonte-Baran","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0365","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1189\/jlb.0212101","article-title":"Targeting the Th17 pathway in psoriasis","volume":"92","author":"Elloso","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2025.103760_bb0370","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cyto.2007.09.014","article-title":"IL-17\/Th17 targeting: on the road to prevent chronic destructive arthritis?","volume":"41","author":"Lubberts","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2025.103760_bb0375","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCRESAHA.111.261784","article-title":"The IL-17A\/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment","volume":"110","author":"Butcher","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0380","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rdc.2020.03.001","article-title":"Autoimmunity, clonal hematopoiesis, and myeloid neoplasms","volume":"46","author":"Bekele","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2025.103760_bb0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0395","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11883-023-01083-5","article-title":"Clonal hematopoiesis: connecting aging and inflammation in atherosclerosis","volume":"25","author":"Polizio","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.autrev.2025.103760_bb0400","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1253\/circj.CJ-21-0505","article-title":"Emerging role of acquired mutations and clonal hematopoiesis in atherosclerosis \u2013 beyond conventional cardiovascular risk factors","volume":"87","author":"Zuriaga","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2025.103760_bb0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-018-0107-2","article-title":"Clonal hematopoiesis in patients with rheumatoid arthritis","volume":"8","author":"Savola","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2025.103760_bb0410","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keac108","article-title":"Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)","volume":"61","author":"David","year":"2022","journal-title":"Rheumatololgy"},{"key":"10.1016\/j.autrev.2025.103760_bb0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0420","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103760_bb0425","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/01.ATV.21.5.791","article-title":"Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model","volume":"21","author":"McPherson","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2025.103760_bb0430","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FJC.0b013e318241c385","article-title":"Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits","volume":"59","author":"Bulgarelli","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.autrev.2025.103760_bb0435","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0440","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","article-title":"Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis","volume":"81","author":"Naerr","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.autrev.2025.103760_bb0445","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial","volume":"69","author":"Charles-Schoeman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103760_bb0450","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0455","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/met.2015.0130","article-title":"Combined elevated levels of the proinflammatory cytokines IL-18 and IL-12 are associated with clinical events in patients with coronary artery disease: an observational study","volume":"14","author":"Opstad","year":"2016","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.autrev.2025.103760_bb0460","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5152\/eurjrheum.2020.20193","article-title":"Positive effect of hydroxychloroquine on lipid profiles of patients with rheumatoid arthritis: a veterans affair cohort","volume":"8","author":"Guevara","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0465","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/medicina58091287","article-title":"Hydroxychloroquine effects on THP-1 macrophage cholesterol handling: cell culture studies corresponding to the TARGET cardiovascular Trial","volume":"58","author":"Ahmed","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.autrev.2025.103760_bb0470","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41598-018-19788-y","article-title":"Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1\/EphA2 system in bladder cancer","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103760_bb0475","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2015.08.054","article-title":"Differential effects of anti-TNF-\u03b1 and anti-IL-12\/23 agents on human leukocyte-endothelial cell interactions","volume":"765","author":"R\u00edos-Navarro","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2025.103760_bb0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ph15010011","article-title":"Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk","volume":"15","author":"Ahmed","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.autrev.2025.103760_bb0485","doi-asserted-by":"crossref","first-page":"606","DOI":"10.55563\/clinexprheumatol\/uiqdtq","article-title":"Up-regulation of autophagy by etanercept treatment results in TNF-induced apoptosis reduction in EA.hy926 endothelial cell line","volume":"39","author":"Barbati","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0490","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.3390\/ijms241612571","article-title":"Effect of the JAK\/STAT inhibitor tofacitinib on macrophage cholesterol metabolism","volume":"24","author":"Adorni","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103760_bb0495","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","article-title":"Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice","volume":"490","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2025.103760_bb0500","doi-asserted-by":"crossref","first-page":"1079185","DOI":"10.3389\/fphar.2022.1079185","article-title":"Advances in immunotherapy modalities for atherosclerosis","author":"Meng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103760_bb0505","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2025.103760_bb0510","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s11936-023-01024-0","article-title":"Immunotherapy-associated atherosclerosis: a comprehensive review of recent findings and implications for future research","volume":"25","author":"Chan","year":"2023","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12865-021-00466-0","article-title":"Reduction of peripheral regulatory T cells in active rheumatoid arthritis patients with coronary artery disease","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0520","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0525","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","article-title":"CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(\u2212\/\u2212) mice","volume":"97","author":"Ma","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0530","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0535","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0540","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007393","article-title":"Comparative cardiovascular risk of Abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study","volume":"7","author":"Kang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.autrev.2025.103760_bb0545","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3899\/jrheum.170926","article-title":"Cardiovascular (CV) risk after initiation of Abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease","volume":"45","author":"Jin","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0550","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.cjca.2020.01.003","article-title":"Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a National Cohort Study","volume":"36","author":"Hsieh","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0555","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.carpath.2004.02.005","article-title":"B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations","volume":"13","author":"Aubry","year":"2004","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.autrev.2025.103760_bb0560","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.117.312513","article-title":"Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry","volume":"122","author":"Winkels","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0565","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH774>3.0.CO;2-N","article-title":"Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses","volume":"193","author":"Houtkamp","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2025.103760_bb0570","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001403","article-title":"A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis","volume":"4","author":"van Dijk","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.autrev.2025.103760_bb0575","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.4049\/jimmunol.0901076","article-title":"Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques","volume":"183","author":"Burioni","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0580","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1161\/ATVBAHA.112.300112","volume":"33","author":"Huan","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2025.103760_bb0585","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.4049\/jimmunol.1202870","article-title":"Characterization of resident B cells of vascular walls in human atherosclerotic patients","volume":"191","author":"Hamze","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0590","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8472","article-title":"Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity","volume":"105","author":"Shaw","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103760_bb0595","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/14737175.6.2.175","article-title":"The effect of infections and vaccinations on stroke risk","volume":"6","author":"Grau","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2025.103760_bb0600","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1471-4906(01)02089-0","article-title":"Atherosclerosis as an autoimmune disease: an update","volume":"22","author":"Wick","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0605","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/antiox8100484","article-title":"Anti-oxidized LDL antibodies and coronary artery disease: a systematic review","volume":"8","author":"van den Berg","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.autrev.2025.103760_bb0610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tcm.2018.05.010","article-title":"Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis \u2013 novel insights and future directions in diagnosis and therapy","volume":"29","author":"Hartley","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0615","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/hq0801.093587","article-title":"Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo","volume":"21","author":"Shaw","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2025.103760_bb0620","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0961203311398884","article-title":"Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome","volume":"20","author":"Laczik","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103760_bb0625","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/08916930902828247","article-title":"oxLDL\/beta2GPI complex and anti-oxLDL\/beta2GPI in SLE: prevalence and correlates","volume":"42","author":"Bassi","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2025.103760_bb0630","first-page":"331","article-title":"Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus","volume":"21","author":"Nowak","year":"2012","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0635","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1196\/annals.1361.071","article-title":"Prevalence of antiphospholipid and antioxidized low-density lipoprotein antibodies in rheumatoid arthritis","volume":"1051","author":"Sherer","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2025.103760_bb0640","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17219\/acem\/29847","article-title":"Disease activity, oxidized-LDL fraction and anti-oxidized LDL antibodies influence cardiovascular risk in rheumatoid arthritis","volume":"25","author":"Nowak","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0645","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0961203307076697","article-title":"Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies","volume":"16","author":"Sherer","year":"2007","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2025.103760_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2025.103760_bb0655","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"293","author":"Frosteg\u00e5rd","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0660","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2013.02.009","article-title":"Antibodies to citrullinated peptides and risk of coronary heart disease","volume":"228","author":"Cambridge","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.autrev.2025.103760_bb0665","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2018-214975","article-title":"First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis","volume":"78","author":"Fent","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0670","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1084\/jem.20100155","article-title":"B cell depletion reduces the development of atherosclerosis in mice","volume":"207","author":"Ait-Oufella","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0675","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001267","article-title":"Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis","volume":"3","author":"Hsue","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.autrev.2025.103760_bb0680","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41569-018-0106-9","article-title":"The role of B cells in atherosclerosis","volume":"16","author":"Sage","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0685","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.117.032790","article-title":"B cell-activating factor neutralization aggravates atherosclerosis","volume":"138","author":"Tsiantoulas","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103760_bb0690","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41598-017-04438-6","article-title":"Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells","volume":"7","author":"Ponnuswamy","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103760_bb0695","doi-asserted-by":"crossref","first-page":"179","DOI":"10.31138\/mjr.32.2.179","article-title":"B-cell activating factor polymorphisms in rheumatoid arthritis-associated atherosclerosis","volume":"32","author":"Kintrilis","year":"2021","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0700","first-page":"152586","article-title":"Metabolic checkpoints in rheumatoid arthritis","author":"Weyand","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0705","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4093\/dmj.2024.0140","article-title":"T-cell senescence in human metabolic diseases","volume":"48","author":"Nga","year":"2024","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.autrev.2025.103760_bb0710","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1161\/01.CIR.0000131450.66017.B3","article-title":"CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients","volume":"109","author":"Gerli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103760_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113722","article-title":"Mitochondria dysfunction: a trigger for cardiovascular diseases in systemic lupus erythematosus","volume":"144","author":"Wang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2025.103760_bb0720","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.2023-0833","article-title":"The link between dysregulated immunometabolism and vascular damage: implications for the development of atherosclerosis in systemic lupus erythematosus and other rheumatic diseases","volume":"51","author":"Yennemadi","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100534","article-title":"Cholesterol trafficking to the ER leads to the activation of CaMKII\/JNK\/NLRP3 and promotes atherosclerosis","volume":"65","author":"Yalcinkaya","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149702","article-title":"High glucose levels accelerate atherosclerosis via NLRP3-IL\/ MAPK\/NF-\u03baB-related inflammation pathways","volume":"704","author":"Sun","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2025.103760_bb0735","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103760_bb0740","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0745","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.autrev.2025.103760_bb0750","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cjca.2020.10.006","article-title":"Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Samuel","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0755","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"NEJM"},{"key":"10.1016\/j.autrev.2025.103760_bb0760","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2025.103760_bb0765","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103760_bb0770","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103760_bb0775","doi-asserted-by":"crossref","DOI":"10.1007\/s00011-023-01845-6","article-title":"Inflammation in heart failure: pathophysiology and therapeutic strategies","author":"Boulet","year":"2024","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0780","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0785","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0790","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled Trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0795","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","article-title":"Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis","volume":"7","author":"Ikonomidis","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.autrev.2025.103760_bb0800","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103760_bb0805","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0810","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003912","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF\u03b1 inhibitor in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.autrev.2025.103760_bb0815","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103760_bb0820","doi-asserted-by":"crossref","first-page":"10","DOI":"10.31138\/mjr.171023.rof","article-title":"Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"35","author":"Partalidou","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0825","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103760_bb0830","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-024-03352-3","article-title":"Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial","volume":"26","author":"Liao","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974826","article-title":"Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: a path to potential biomarkers","volume":"13","author":"Guzm\u00e1n-Mart\u00ednez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103760_bb0840","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/ITT.S377076","article-title":"Managing cardiovascular risk in systemic lupus erythematosus: considerations for the clinician","volume":"12","author":"Semalulu","year":"2023","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.autrev.2025.103760_bb0845","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11883-023-01149-4","article-title":"Atherosclerosis in systemic lupus erythematosus","volume":"25","author":"Tobin","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.autrev.2025.103760_bb0850","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103760_bb0855","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103760_bb0860","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/JIR.S282691","article-title":"Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction","volume":"14","author":"Fragoulis","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103760_bb0865","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejim.2023.12.027","article-title":"A systematic literature review of randomised controlled trials evaluating colchicine for cardiovascular prevention: there is an elephant in the room","volume":"125","author":"Alunno","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T13:37:49Z","timestamp":1740922669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":173,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1568997225000205"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103760","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103760"}}